HMGN1 and acute myeloid leukemia: Although the overall survival was not significantly different in the primary transplant recipients of HMGN1-OE plus AML-ETO9a compared to wild-type plus AML-ETO9a (Fig. 5e), we tested for phenotypic differences in the diseases.